↓ Skip to main content

Therapeutic targeting of VEGF and/or TGF-β to enhance anti-PD-(L)1 therapy: The evidence from clinical trials

Overview of attention for article published in Frontiers in oncology, July 2022
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (86th percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news
1 news outlet
twitter
1 X user
patent
1 patent

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
12 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Therapeutic targeting of VEGF and/or TGF-β to enhance anti-PD-(L)1 therapy: The evidence from clinical trials
Published in
Frontiers in oncology, July 2022
DOI 10.3389/fonc.2022.905520
Pubmed ID
Authors

Linwei Li, Qinglian Wen, Ruilin Ding

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 12 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 12 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 2 17%
Student > Postgraduate 2 17%
Student > Ph. D. Student 1 8%
Unspecified 1 8%
Other 1 8%
Other 0 0%
Unknown 5 42%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 2 17%
Pharmacology, Toxicology and Pharmaceutical Science 1 8%
Unspecified 1 8%
Medicine and Dentistry 1 8%
Engineering 1 8%
Other 0 0%
Unknown 6 50%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 February 2024.
All research outputs
#2,929,886
of 26,169,168 outputs
Outputs from Frontiers in oncology
#739
of 22,913 outputs
Outputs of similar age
#60,529
of 438,122 outputs
Outputs of similar age from Frontiers in oncology
#46
of 1,743 outputs
Altmetric has tracked 26,169,168 research outputs across all sources so far. Compared to these this one has done well and is in the 88th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,913 research outputs from this source. They receive a mean Attention Score of 3.1. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 438,122 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 1,743 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.